中国药物警戒 ›› 2024, Vol. 21 ›› Issue (2): 229-234.
DOI: 10.19803/j.1672-8629.20230152
王欣, 史磊磊, 张雨涵, 谢允东*, 刘继平
收稿日期:
2023-03-21
出版日期:
2024-02-15
发布日期:
2024-02-06
通讯作者:
王欣,女,在读硕士,中药神经药理学。
作者简介:
*谢允东,男,博士,副教授,中药物质质量与安全性评价。E-mail: eng522@126.com
基金资助:
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong*, LIU Jiping
Received:
2023-03-21
Online:
2024-02-15
Published:
2024-02-06
摘要: 肝脏是人体新陈代谢最旺盛的器官,也是体内多种药物的解毒器官。当长期或过量使用药物时会增加药物性肝损伤(DILI)的风险。多药耐药相关蛋白(MRPs)是位于细胞膜上的功能蛋白,可转运多种药物,在DILI中发挥重要作用。MRPs功能的抑制、缺失是药物肝毒性产生的重要原因。本文对MRPs的结构、表达部位及功能进行归纳,并对MRPs与DILI的关系及其改善DILI的机制进行总结,期望更好地了解MRPs转运体与DILI的关系,为后续防治DILI提供参考。
中图分类号:
王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping. The role of MRPs transporters in drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
[1] YAO KY, ZHANG SQ, JIN R, et al.Comparative study on date set of drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 568-573. [2] SHEN T, LIU Y, SHANG J, et al.Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. [3] LIU RJ, XIN XJ.Research advances in pathogenesis, risk factors, monitoring, and retreatment of drug-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(4): 968-973. [4] WANG ST, QIU CX, WANG FL, et al.Research progress in safety of herb-drug interactions mediated by metabolizing enzymes and transporters[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 18-23. [5] BICKERS SC, BENLEKBIR S, RUBINSTEIN JL, et al. Structure of Ycf1p reveals the transmembrane domain TMD0 and the regulatory region of ABCC transporters[J]. Proc Natl Acad Sci USA, 2021, 118(21): eiti2121118. [6] WANG JQ, YANG Y, CAI CY, et al.Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance[J]. Drug Resist Updat, 2021, 54: 100743. [7] ZHANG YK, WANG YJ, GUPTA P, et al.Multidrug resistance proteins (MRPs) and cancer therapy[J]. AAPS J, 2015, 17(4): 802-812. [8] CONSEIL G, COLE S.The first cytoplasmic loop in the core structure of the ABCC1 (multidrug resistance protein 1; MRP1) transporter contains multiple amino acids essential for its expression[J]. Int J Mol Sci, 2021, 22(18): 9718. [9] YIN JY, ZHANG J.Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application[J]. Journal of Central South University(Medical Scienses)(中南大学学报医学版), 2011, 36(10): 927-938. [10] COLE SP.Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future[J]. Annu Rev Pharmacol Toxicol, 2014, 54: 95-117. [11] ZHANG Y, ZHANG Y, LI J, et al.The role of hepatic antioxidant capacity and hepatobiliary transporter in liver injury induced by isopsoralen in zebrafish larvae[J]. Hum Exp Toxicol, 2019, 38(1): 36-44. [12] DU FB, MEI XD.The progress of multidrug resistance-associated protein 2(MRP2) and its role in cancer drug resistance[J]. Journal of Modern Oncology(现代肿瘤医学), 2008(3): 478-480. [13] CHEN Z, SHI T, ZHANG L, et al.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade[J]. Cancer Lett, 2016, 370(1): 153-164. [14] WU L, LI Y, SONG Y, et al.A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China[J]. Orphanet J Rare Dis, 2020, 15(1): 74. [15] OU QQ, QIAN XH, LI DY, et al.Yinzhihuang attenuates ANIT-induced intrahepatic cholestasis in rats through upregulation of Mrp2 and Bsep expressions[J]. Pediatr Res, 2016, 79(4): 589-595. [16] ZONG SD, ZHANG H.Research progress of MRP3 and MRP4 transporters in tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2019, 24(3): 327-331. [17] ALI I, WELCH MA, LU Y, et al.Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay[J]. Eur J Pharm Sci, 2017, 103: 52-59. [18] JEONG ES, KIM G, SHIN HJ, et al.Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis[J]. Toxicol Appl Pharmacol, 2015, 288(2): 213-222. [19] BANERJEE M, MARENSI V, CONSEIL G, et al.Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions[J]. Biochem Pharmacol, 2016, 120: 72-82. [20] KOCK K, FERSLEW BC, NETTERBERG I, et al.Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4[J]. Drug Metab Dispos, 2014, 42(4): 665-674. [21] OSTUNI A, CASTIGLIONE MM, CUVIELLO F, et al.Structural characterization of the L0 cytoplasmic loop of human multidrug resistance protein 6 (MRP6)[J]. Biochim Biophys Acta Biomembr, 2019, 1861(2): 380-386. [22] WU Y, WU SM.Protective effects of extracts of Sibraea angustata on hepatic injury induced by combining isoniazid with rifampicin in mice[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2010, 30(19): 1660-1663. [23] WANG HG, WU Y, YUE HP.The effect of extracts Sibraea angustata on the expression of Mrp2 and Mrp6 of INH- induced hepatotoxicity in mice[J]. Lishizhen Medicine and Materia Medica Research(时珍国医国药), 2016, 27(11): 2594-2595. [24] HONORAT M, TERREUX R, FALSON P, et al.Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2’-deoxyuridine-5’-monophosphate on ABCC11 in silico models[J]. BMC Struct Biol, 2013, 13: 7. [25] SODANI K, PATEL A, KATHAWALA RJ, et al.Multidrug resistance associated proteins in multidrug resistance[J]. Chin J Cancer, 2012, 31(2): 58-72. [26] ISHIKAWA T, TOYODA Y, YOSHIURA K, et al.Pharmacogenetics of human ABC transporter ABCC11: new insights into apocrine gland growth and metabolite secretion[J]. Front Genet, 2012, 3: 306. [27] YUN H, WU X, DING Y, et al.Exploring the mechanism of swertia mussotii Franch. for hepatoprotective effects with iTRAQ LC-MS/MS[J]. Comb Chem High Throughput Screen, 2021, 24(9): 1332-1339. [28] PHAM DH, KUDIRA R, XU L, et al.Deleterious variants in abcc12 are detected in idiopathic chronic cholestasis and cause intrahepatic bile duct loss in model organisms[J]. Gastroenterology, 2021, 161(1): 287-300. [29] MEGARAJ V, IIDA T, JUNGSUWADEE P, et al.Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters[J]. Drug Metab Dispos, 2010, 38(10): 1723-1730. [30] CSANDL MA, CONSEIL G, COLE SP.Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4)[J]. Drug Metab Dispos, 2016, 44(6): 857-866. [31] XU R, WANG Q, ZHANG J, et al.Changes in pharmacokinetic profiles of acetaminophen and its glucuronide after pretreatment with combinations of N-acetylcysteine and either glycyrrhizin, silibinin or spironolactone in rat[J]. Xenobiotica, 2014, 44(6): 541-546. [32] JIA Y, LIU Z, HUO X, et al.Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 [33] GREEN BR, BAIN LJ.Mrp2 is involved in the efflux and disposition of fosinopril[J]. J Appl Toxicol, 2013, 33(6): 458-465. [34] ZALUPS RK, JOSHEE L, BRIDGES CC.Novel Hg2+-induced nephropathy in rats and mice lacking Mrp2: evidence of axial heterogeneity in the handling of Hg2+ along the proximal tubule[J]. Toxicol Sci, 2014, 142(1): 250-260. [35] MCGILL MR, JAESCHKE H.Animal models of drug-induced liver injury[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 1031-1039. [36] JING J, HE TT, BAI ZF, et al.An excerpt from AASLD Practice Guidance on drug, herbal and dietary supplement-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2022, 38(10): 2219-2223. [37] HOSACK T, DAMRY D, BISWAS S.Drug-induced liver injury: a comprehensive review[J]. Therap Adv Gastroenterol, 2023, 16: 1108346386. [38] KOENDERINK JB, VAN DEN HEUVEL J, BILOS A, et al. Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates[J]. Arch Toxicol, 2020, 94(9): 3027-3032. [39] QU X, ZHANG Y, ZHANG S, et al.Dysregulation of BSEP and MRP2 may play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 Cells[J]. Biol Pharm Bull, 2018, 41(8): 1211-1218. [40] FENG H.Research progress on drug-induced cholestasis induced liver injury[J]. Modern Medicine and Health Research Electronic Journal(现代医学与健康研究电子杂志), 2021, 5(8): 132-135. [41] GARZEL B, ZHANG L, HUANG SM, et al.A change in bile flow: looking beyond transporter inhibition in the development of drug-induced cholestasis[J]. Curr Drug Metab, 2019, 20(8): 621-632. [42] GAO YD, ZHU A, LI LD, et al.Cytotoxicity and underlying mechanism of evodiamine in HepG2 cells[J]. Journal of Peking University (Health Science)(北京大学学报医学版), 2021, 53(6): 1107-1114. [43] SU HZ, LI Y, ZHANG ZR, et al.Protecting effects and mechanisms of Yinchenhao decoction on ANIT induced intrahepatic cholestasis in mice[J]. Shanghai Journal of Traditional Chinese Medicine(上海中医药杂志), 2017, 51(S1): 172-176. [44] LI XM, ZHANG XB.Drug induced liver injury[J]. Dermatology Bulletin(皮肤科学文摘), 2016, 33(6): 771-776. [45] FU D, CARDONA P, HO H, et al.Novel mechanisms of valproate hepatotoxicity: impaired mrp2 trafficking and hepatocyte depolarization[J]. Toxicol Sci, 2019, 171(2): 431-442. [46] KAST HR, GOODWIN B, TARR P T, et al.Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor[J]. J Biol Chem, 2002, 277(4): 2908-2915. [47] ZHANG Y, LICKTEIG AJ, LIU J, et al.Effects of ablation and activation of Nrf2 on bile acid homeostasis in male mice[J]. Toxicol Appl Pharmacol, 2020, 403: 115170. [48] ZHANG X, WANG T, YANG Y, et al.Tanshinone IIA attenuates acetaminophen-induced hepatotoxicity through HOTAIR-Nrf2-MRP2/4 signaling pathway[J]. Biomed Pharmacother, 2020, 130: 110547. [49] NING C, GAO X, WANG C, et al.Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating Nrf2 signaling pathway [50] WANG X.Effect of ursolic acid on Nrf2/UGT2B7/BSEP/MRP2 regulatory pathway in liver injury rats and its mechanism[D]. Nanchang: Nanchang University(南昌大学), 2020. [51] GUO HL, HASSAN HM, ZHANG Y, et al.Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport[J]. Toxicol Sci, 2016, 152(2): 417-428. [52] HU Y.Study on the role of bilirubin in cholestatic liver injury induced by oleanolic acid based on FXR and Nrf2 pathways[D].Zunyi: Zunyi Medical University(遵义医科大学), 2022. [53] CHEN H, ZHAO W, YU H, et al.Study on the protective effect of Semen plantaginis aqueous extract against cyclophosphamide induced liver injury in rats, through FXR-mediated regulation of MRP2/BSEP pathway[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2018, 34(5): 85-90. [54] MOTTINO AD, CATANIA VA.Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents[J]. World J Gastroenterol, 2008, 14(46): 7068-7074. [55] ZHOU X, BI H, JIN J, et al.Effects of praeruptorin A and praeruptorin C, a racemate isolated from peucedanum praeruptorum, on MRP2 through the CAR pathway[J]. Planta Med, 2013, 79(17): 1641-1647. [56] FU R, WANG XN, DING CY, et al.Advances in the study of pregnane X receptor in drug-induced liver injury[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(7): 892-896. [57] WANG LL, YU C.Effects of paeonol on the expression and function of MRP2 in HepG2 cells[J]. Journal of Chongqing Medical University(重庆医科大学学报), 2016, 41(2): 164-167. [58] WANG MT.The role of PXR-MRP2 pathway in cyclosporine-induceddrug-induced liver injury[D]. Wuhan: Hubei University of Chinese Medicine(湖北中医药大学), 2020. [59] LIU C, LI SX, GAO Y, et al.Alcohol extract of Swertia mussitii Franch upregulates membrane protein MRP3, nuclear transcription factor SP1 and nuclear receptors PXR and CF in HepG2 cells[J]. Journal of Army Medical University(第三军医大学学报), 2014, 36(10): 1008-1011. |
[1] | 高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39. |
[2] | 詹姆斯·布坎南. 用 nR 改良海氏法则及 PALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120. |
[3] | 陈崇泽, 李婕, 旷煉, 檀学文, 刘敏惠, 刘熙, 郑燕钗, 靳洪涛. 448例住院患者药物性肝损伤相关不良反应特征分析[J]. 中国药物警戒, 2023, 20(6): 697-704. |
[4] | 罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504. |
[5] | 李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510. |
[6] | 姚克宇, 张舒琪, 金锐, 刘丽红, 朱彦. 药物致肝损伤数据集的比较研究[J]. 中国药物警戒, 2023, 20(5): 568-573. |
[7] | 陈超, 朱兰, 刘丽红, 韩佳寅, 朱彦. 文献来源的补骨脂及其制剂引起药物性肝损伤特点探析[J]. 中国药物警戒, 2023, 20(4): 449-453. |
[8] | 王宇, 黄婧怡, 侯立新, 李爽, 崔永康, 黄兰蔚. 社区获得性肺炎患者抗生素相关性肝损伤外周血体液免疫特点分析[J]. 中国药物警戒, 2023, 20(2): 132-135. |
[9] | 于洁, 朱浩翔, 张继明. 疑似千里光类药物致药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 136-139. |
[10] | 李晓娟, 张爱武, 魏颖. 伤风停胶囊致急性药物性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(2): 213-214. |
[11] | 魏安华, 漆建军, 王璐, 曾露, 贡雪芃, 江莹. 953例口服降糖药不良反应/事件报告分析[J]. 中国药物警戒, 2023, 20(12): 1415-1420. |
[12] | 陈刚, 李岩, 姜彩虹, 解沛涛, 苏长海. 索凡替尼片和羟考酮缓释片致深度昏迷和重度药源性肝损伤1例分析[J]. 中国药物警戒, 2023, 20(11): 1296-1298. |
[13] | 汪祺, 杨建波, 王莹, 马双成, 文海若. 基于转运体探讨何首乌提取物对大鼠肾脏的影响[J]. 中国药物警戒, 2022, 19(6): 626-629. |
[14] | 魏仙妮, 许惠溢, 黄宇虹, 谢根英. 100例药物性肝损伤的影响因素与治疗方法分析[J]. 中国药物警戒, 2022, 19(6): 665-669. |
[15] | 聂晓璐, 彭亚光, 孙子墨, 彭晓霞. 药物性肝损伤诊断相关生化指标阈值制定的研究现状及思考[J]. 中国药物警戒, 2022, 19(3): 244-247. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||